Company: CMND
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001213900-25-109567
Chunk: 31

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 31
---
 the sale
of the securities we are offering pursuant to this prospectus supplement to institutional investors through a securities purchase agreement
directly between the purchasers and us. All of the shares will be sold at the same price and, we expect, at a single closing. We established
the price following negotiations with the prospective investors and with reference to the prevailing market price of our Common Shares,
recent trends in such price and other factors. It is possible that not all of the securities we are offering pursuant to this prospectus
supplement will be sold at the closing, in which case our net proceeds would be reduced. We expect that the sale of the securities will
be completed on or around the date indicated on the cover page of this prospectus supplement.

The Common Shares and/or
pre-funded warrants may not be sold in Canada or to or for the benefit of a Canadian resident. By purchasing the securities offered pursuant
to this prospectus supplement, the purchaser undertakes not to sell such securities in Canada or to a person resident in Canada prior
to the expiry of a period of four months and one day from closing of this offering.

<div align='center'>LEGAL MATTERS</div>

The validity of the issuance
of our Common Shares offered hereby and certain other matters of Canadian law will be passed upon for us by Daniel N. Bloch. Certain matters
of U.S. federal securities law relating to this offering will be passed upon for us by Greenberg Traurig, P.A., Tel Aviv, Israel.

<div align='center'>EXPERTS</div>

The financial statements of
Clearmind Medicine Inc. as of October 31, 2024 and 2023 and for the years then ended, as included in this prospectus supplement, have
been audited by Brightman Almagor Zohar & Co., a firm in the Deloitte global network, an independent registered public accounting
firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given the firm’s
authority as experts in accounting and auditing.

The audit report covering
the October 31, 2024 consolidated financial statements contains an explanatory paragraph that states that the Company’s recurring
losses from operations and lack of sufficient resources raise substantial doubt about the entity’s ability to continue as a going
concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.

Such financial statements
are incorporated in this prospectus supplement by reference in reliance upon such